Advertisement

Etoposid — Chemie, präklinische und klinische Pharmakologie

  • R. Raettig
  • N. Niederle
  • W. Achterrath
  • Gadner
  • Lutz
  • Raettig
  • Schmalzl
  • Schwarzmeier
  • Willemze

Zusammenfassung

Bereits vor mehreren hundert Jahren verwendeten die nordamerikanischen Indianer und die Bewohner des Himalaja den wäßrigen Extrakt aus Podophyllum peltatum (American mandrake, May apple) bzw. Podophyllum emodi als Abführmittel und als Antihelminthikum (8, 36, 40, 50). Auch die erste amerikanische Pharmakopöe von 1820 verzeichnete diese Extrakte als Emetikum. Podophyllin wurde erst 1942 wegen erheblicher Nebenwirkungen aus der Pharmakopoe gestrichen. Im selben Jahr wurde ein öliger Extrakt aus dieser Pflanze von Kaplan zur Behandlung von Condyloma acuminata sowie anderer gutartiger Hauterkrankungen verwendet (37), und 1946 publizierten King und Mitarbeiter über die mitosehemmende Wirkung dieses Extrakts in Science (36, 41).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Allen, L. M Creaven, P.J: Comparison of the human pharmacokinetics of VM 26 and VP16, two antineoplastic epipodophyllotoxin glucopyrano- side derivatives. Eur. J. Cancer 11, 697–707 (1975).PubMedCrossRefGoogle Scholar
  2. 2.
    Allen, L. M., Mareks, C., Creaven, P. J: 4’Demethyl-epipodophyllic acid-9-(4,6-ethylidene-/?-D-glucopyranoside), the major urinary metabolite of VP 16-213 in man. Proc. Am. Ass. Cancer Res. & Am. Soc. clin. Oncol. 17, 6 (1976).Google Scholar
  3. 3.
    Allen, L. M., Shirley, M: Mechanism of cellular transport of two epi-podophyllotoxin glucopyranoside derivatives, VM 26 (VM) and VP16 (VP). Proc. Am. Ass. Cancer Res. & Am. Soc. clin. Oncol. 18, 22 (1977).Google Scholar
  4. 4.
    Allen, L. M: Comparison of uptake and binding of two epipodophyllo- toxinglucopyranosides, 4’-demethyl epipodophyllotoxin thenylidene-ß-D- glucoside and 4’-demethyl epipodophyllotoxin ethylidene-ß-D-glucoside, in the L1210 leukemia cell. Cancer Res.38, 2549–2554 (1978).PubMedGoogle Scholar
  5. 5.
    Arnold, A. M: Podophyllotoxin derivate VP 16-213. Cancer Chemother. Pharmacol. 3, 71–80 (1979).Google Scholar
  6. 6.
    Arnold, A. M., Whitehouse, J. M. A: Interaction of VP 16-213 with the DNA Repair Antagonist Chloroquine. Cancer Chemother. Pharmacol. 7, 123–126 (1982).Google Scholar
  7. 7.
    Barlogie, B Drewinko: B Cell cycle stage-dependent induction of G2- phase arrest by different antitumor agents. Eur. J. Cancer 14 741–745 (1978).Google Scholar
  8. 8.
    Bentley, R: New American remedies. 1: Podophyllum peltatum. Pharm. J. Trans. 8, 456–464 (1961).Google Scholar
  9. 9.
    Brewer, C. F., Loike, J. D., Horwitz, J. Sternlicht, H., Gensler, W. J: Conformational analysis of podophyllotoxin and its congeners. Structure-activity relationship in microtubule assembly. J. Med. Chem. 22, 215–221 (1979).PubMedCrossRefGoogle Scholar
  10. 10.
    Burchenal, J. Kalaher, K., Lokys, L., Gale, G: Studies of cross- resistance, synergistic combinations and blocking of activity of platinum derivatives. Biochimie 60, 961–965 (1978).CrossRefGoogle Scholar
  11. 11.
    Burchenal, J. H., Lokys, L., Turkevich, J., Gale, G: Rationale of combi- nation chemotherapy. In: Cisplatin - Current Status and New Developments (.Prestayko, A W., Crooke, S. T., Carter, S.K Hrsg.), S. 113. New York-London-Toronto-Sydney-San Francisco: Academic Press. 1980.Google Scholar
  12. 12.
    Chiuten, D. F., Wodinsky, I., Abraham, D: Influence of treatment schedule on the toxicity and antitumor activity of mitotic inhibitors and semisynthetic podophyllotoxin derivatives. Proc. Am. Ass. Cancer Res. & Am. Soc. clin. Oncol. 20, 402 (1979).Google Scholar
  13. 13.
    Corbett, T. H. Griswold, Z X P., Roberts, B. Peckham, J. C., Schabet, F. M: Biology and therapeutic response of a mouse mammary adeno- carcinoma (16 C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat. Rep. 62, 1471–1488 (1978).PubMedGoogle Scholar
  14. 14.
    Creasy, W. A: Vincaalkaloids and colchinine. In: Antineoplastic and Immunsuppressive Agents II (Sartorelli, A C., Johns, D. G., Hrsg.), S. 670. Berlin-Heidelberg-New York: Springer. 1975.Google Scholar
  15. 15.
    Creasy, W. A: The vincaalkaloids. In: Mechanism of Action of Anti- eukaryotic and Antiviral Compounds (Hann, F. E., Hrsg.), S. 414. Berlin-Heidelberg-New York: Springer. 1979.Google Scholar
  16. 16.
    Creaven, P.J: The clinical pharmacology of VM 26 and VP 16-213. A brief overview. Cancer Chemother. Pharmacol. 7, 133–140 (1982).Google Scholar
  17. 17.
    Creaven, P. J., Allen, L. M: EPEG, a new antineoplastic epipodophyllo toxin. Clin. Pharm. Therap. 18, 221–256 (1975).PubMedGoogle Scholar
  18. 18.
    Dombernowsky, P., Nissen, N. L: Schedule dependency of the anti- leukemia activity of the podophyllotoxin-derivative VP 16-213 (NSC 141540) in L1210 leukemia. Acta path. microbiol. scand. A81, 715–724 (1973).Google Scholar
  19. 19.
    Dombernowsky, P., Nissen, N. L: Combination chemotherapy with 4’- demethylepipodophyllotoxin 9-(4,6–0-ethylidene-ß-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia. Eur. J. Cancer 72, 181–188 (1976).Google Scholar
  20. 20.
    Drewinko, B., Barlogie, B: Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP 16-213. Cancer Treat. Rep.60, 1295–1306 (1976).PubMedGoogle Scholar
  21. 21.
    Drewinko, B., Barlogie, B: Differences in the killing efficacy of antitumor drugs on proliferating (P) and nonproliferating (NP) human cells. Proc. Am. Ass. Cancer Res. & Am. Soc. clin. Oncol. 27, 285 (1980).Google Scholar
  22. 22.
    Drewinko, B: Cellular pharmacology. In: Cancer and Chemotherapy; Introduction to Neoplasia and Antineoplastic Chemotherapy (Crooke, S. T.Y Prestayko, A. W., Hrsg.), Vol. 1, S. 95. New York-London-Toron- to-Sydney-San Francisco: Academic Press. 1980.Google Scholar
  23. 23.
    D’Incalci, M., Farina, P. Sessa, C., Molina, P., Mangioni, C., Jancovich, M., Masera, G., Beer, M., Cavalli, F: Pharmakokinetic of VP16 in humans. Chemioterapia 1, 126–129 (1982).Google Scholar
  24. 24.
    D’Incalci, M., Farina, P., Fasoli, M., Marsoni, S: VP16 plasma levels after i.v. and two methods of oral administration to choriocarcinoma patients. Proc. Am. Ass. Cancer Res. & Am. Soc. clin. Oncol. 22, 357 (1981).Google Scholar
  25. 25.
    D’Incalci, M., Farina, P., Sessa, C., Mangioni, C., Conter, V., Masera, G., Rocchetti, M., Brambilla Pisoni, M., Piazza, F., Beer, M., Cavalli, F: Pharmacokinetics of VP 16-213 given by different administration methods. Cancer Chemother. Pharmacol. 7, 141–145 (1982).PubMedGoogle Scholar
  26. 26.
    Evans, W. E., Sinkule, M. A., Crom, W. R., Dow, L., Look, T., Horvath, A., Rivera, G: Pharmacokinetics of Etoposide (VP16) in children with leukemia. Chemioterapia 1, 122–125 (1982).Google Scholar
  27. 27.
    Evans, W. E., Sinkule, M. A., Horvath, A., Crom, W. R., Dow, L. W., Rivera, G: Clinical pharmacology of VM 26 (NSC 122819) and VP16 (NSC 141540) in children with cancer. Proc. Am. Ass. Cancer Res. & Am. Soc. Clin. Oncol. 22, 174 (1981).Google Scholar
  28. 28.
    Farina, P., Marzillo, G., D’Incalci, M: High-performance liquid chroma- tography determination of 4’-demethylepipodophyllotoxin-9-(4,6–0-ethy- lidene-ß-D-glucopyranoside) (VP 16-213) in human plasma. J. Chrom. 222, 141–145 (1981).CrossRefGoogle Scholar
  29. 29.
    Fiebig, H. J., Lohr, G. W: Transplantation of human stomach cancers in nude mice and their responsiveness to chemotherapy. Proc. Am. Ass. Cancer Res. & Am. Soc. clin. Oncol. 22, 266 (1980).Google Scholar
  30. 30.
    Grieder, A., Maurer, R., Stähelin, H: Effect of an epipodophyllotoxin derivate (VP 16-213) on macromolecular synthesis and mitosis in masto- cytoma cells in vitro. Cancer Res. 34, 1788–1793 (1974).PubMedGoogle Scholar
  31. 31.
    Grieder, A., Maurer, R., Stähelin, H: Comparative study of early effects of epipodophyllotoxin-derivatives and other cytostatic agents on masto- cytoma cultures. Cancer Res. 37, 2998–3005 (1977).PubMedGoogle Scholar
  32. 32.
    Hände, K. R., McKay, C. M., Wedlund, P. J., Noone, R. M., Shea, W. K., Fer, M. F., Greco, F. A., Wolff, S. N: Clinical pharmacology of high dose VP 16-213. Proc. Am. Ass. Cancer Res. 23, 131, AACR Abstr. 513 (1982).Google Scholar
  33. 33.
    Ho, D. H. W., Kanellopoulos, K. A., Yap, H. Y., Casimir, M., Savaraj, M., Savaraj, N., Issell, B Benjamin, Ä. S., Bodey, G. P: Clinical pharmacology of Etoposide by radioimmunoassay. Proc. Am. Ass. Cancer Res. 24, 131, AACR Abstr. 519 (1983).Google Scholar
  34. 34.
    Holthuis, J. J. M ., Postmus, P. E., Sleijfer, D Th, Mulder N. H., Verleun, H., van Oort, W. J: Pharmacokinetics of Etoposide (VP 16-213) after high dose intravenous administration. 2nd Eur. Conf. Clin. Oncol., Amsterdam, 2. bis 5. November 1983, S. 13, Abstr. 02–19.Google Scholar
  35. 35.
    Huang, C. C., Hou, Y., Wang, M. M: Effects of a new antitumor agent, epipodophyllotoxin, on growth and chromosomes in human hematopoetic cell lines. Cancer Res. 33, 3123–3129 (1973).PubMedGoogle Scholar
  36. 36.
    Isseil, B. F., Crooke, S. T: Etoposide (VP 16-213). Cancer Treat. Rev. 6, 107–124 (1979).CrossRefGoogle Scholar
  37. 37.
    Kaplan, J. W: Condyloma acuminata. New Orleans Med. Surg. J.94, 388–390 (1942).Google Scholar
  38. 38.
    Kelleher, M. K: Correlation of tubulin-binding and antitumor activities of podophyllotoxin analogs. Cancer Treat. Rep. 62, 1443–1447 (1978).PubMedGoogle Scholar
  39. 39.
    Keller-Juslen, C., Kuhn, M., v. Wartburg, A,Stähelin, H: Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxin. J. Med. Chem. 14, 936–940 (1971).PubMedCrossRefGoogle Scholar
  40. 40.
    Kelly M. G. Hartwell, M. L: The biological effects and the chemical composition of podophyllin. A review. J. Nat. Cancer Inst. 14, 946–1010 (1954).Google Scholar
  41. 41.
    King, L., Sullivan, M: Similarity of effects of podophyllin and colchicine and news in treatment of Condyloma acuminata. Science104, 244–245 (1946).CrossRefGoogle Scholar
  42. 42.
    Krishan, A., Paika, K., Frei, E: Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM 26, VP 16-213) on the cell cycle traverse of human lymphoblasts. J. Cell. Biol. 66, 521–530 (1975).PubMedCrossRefGoogle Scholar
  43. 43.
    Kühl, M., Sauer, H., Wilmanns, W: Inhibition of deoxyuridine (dUR) uptake by Etoposide (VP 16-213) into human lymphoblasts: Investigation on the mode of action. 13th Intern. Congr. Chemother., Wien, 18. August bis 2. September 1983, Teil 262, S. 37–40.Google Scholar
  44. 44.
    Loike, J. D.: Effects of podophyllotoxin and VP 16-213 on microtubule assembly in vitro and nucleoside transport in Heia cells. Bio- chem. 15, 5435–5442 (1976).Google Scholar
  45. 45.
    Loike, J. D., Horwitz, S. B: Effect of VP 16-213 on the intracellular degradation of DNA in Heia cells. Biochem.15, 5443–5448 (1976).CrossRefGoogle Scholar
  46. 46.
    Loike, J. D., Brewer, C.F., Sternlicht, H., Gensler, W.M., Horwitz, S. B: Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners. Cancer Res. 38, 2688–2693 (1978).PubMedGoogle Scholar
  47. 47.
    Mabel, J. A., Little, A. D: Therapeutic synergism in murine tumors for combinations of cis-dichlorodiammineplatinum with VP 16-213 or BCNU. Proc. Am. Ass. Cancer Res. Am. Soc. clin. Oncol. 20, 230 (1979).Google Scholar
  48. 48.
    Miller, A. A., Schmidt, C. G: Clinical pharmacology of Etoposide (VP16) administered as continuous intravenous infusion. 2nd Eur. Conf. Clin. Oncol., Amsterdam, 2. bis 5. November 1983, S. 10, Abstr. 02–02.Google Scholar
  49. 49.
    Osieka, R: Persönliche Mitteilung. 1981.Google Scholar
  50. 50.
    Osswald, H: Antineoplastische Chemotherapeutika. In: Maligne Tumoren (Schmähl, D., Hrsg.), S. 396. Aulendorf: Editio Cantor. 1981.Google Scholar
  51. 51.
    Pelsor, F. R., Allen, L. M., Creaven, P.M: Multicompartment pharmaco- kinetic model of 4’-demethylepipodophyllotoxin-9-(4,6–0-ethylidene-/3- D-glucopyranoside) in humans. J. pharm. Sei. 67, 1106–1108 (1978).CrossRefGoogle Scholar
  52. 52.
    Pflüger, K.-H Jungclas, H., Danigel, H., Schmidt, L., Dellbrügge, M., Havemann, K: Pharmacokinetics of Etoposide determined by combined liquid chromatography/mass spectrometry. 2nd Eur. Conf. Clin. Oncol., Amsterdam, 2. bis 5. November 1983, S. 15, Abstr. 02–25.Google Scholar
  53. 53.
    Postmus, P. F., Holthuis, J. J. M., Haaxma-Reiche, H., Mulder, N. H., Vencken, L. M., van Oort, W.M., Sleijfer, D. Th., Sluiter, H.M: High dose VP 16-213 for progressive CNS metastases of small cell lung cancer. 13th Intern. Congr. Chemother., Wien, 28. August bis 2. September 1983, Teil 281, S. 9–11.Google Scholar
  54. 54.
    Postmus, P. E Mulder, N. F L., Sleijfer, D. Th., Meines, A. F., Vriesendorp, R., de Vries, E. G. E., Willemse, P. H. B: High dose VP 16-213 (HD-VP) for refractory malignancies, a phase I study. 2nd Eur. Conf. Clin. Oncol., Amsterdam, 2. bis 5. November 1983, S. 62, Abstr. 06–12.Google Scholar
  55. 55.
    Preisler, H B jörnsson, S: Chemotherapeutic sensitivity of murine myeloid leukemia. In: Advances in Comparative Leukemia Research 1977. Proceedings of the VIII. Intern. Symp. on Comparative Research on Leukemia and Related Diseases, New York, 22. bis 26. August 1977, S. 428–430. Elsevier/North-Holland, Biomedical Press. 1977.Google Scholar
  56. 56.
    Rao, P. N: G2 arrest induced by anticancer drugs. In: Effects of Drugs on the Cell Nucleolus (Busch, H., Crooke, S. T., Daskal, Y., Hrsg.), S. 475. New York-London-Toronto-Sydney-San Francisco: Academic Press. 1979.Google Scholar
  57. 57.
    Rivera, G., Avery, T., Roberts, D. W: Response of L1210 to combinations of cytosine arabinoside and VM 26 or VP 16-213. Eur. J. Cancer 11, 639–647 (1975).PubMedCrossRefGoogle Scholar
  58. 58.
    Sandoz Pharma: Zusammenfassung VP 16-213. Pharmakokinetik (1976).Google Scholar
  59. 59.
    Sandoz Pharma: VP 16-213 Chemie, Pharmakologie. Zusammenfassung (1979).Google Scholar
  60. 60.
    Sandoz Pharma: Etoposid - Animal Pharmacology and Pharmacokinetics. Zusammenfassung (1979).Google Scholar
  61. 61.
    Sandoz Pharma: VP 16-213 Zusammenfassung, präklinische Pharmakologie (1979).Google Scholar
  62. 62.
    Schabel, F. M., Griswold, D. P., Corbett, T. H., Laster, W. R., Mayo, J. G., Lloyd, H. H: Testing therapeutic hypotheses in mice and man: ob- servations on the therapeutic activity against advanced solid tumors of mice treated with anticancer drugs that have demonstrated or potential clinical Utility of treatment of advanced solid tumors of man. In: Methods in Cancer Research XVII: Cancer Drug Development (DeVita, V. D., Busch, H., Hrsg.), Teil B, S. 3. New York-San Francisco-London: Academic Press. 1979.Google Scholar
  63. 63.
    Schabel, F. M., Trader, M. W., Laster, W. R., Corbett, T. H., Griswold, D. P: Cis-diaminedichloroplatinum (II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat. Rep. 63, 1459–1473 (1979).PubMedGoogle Scholar
  64. 64.
    Seeber, S., Osieka, R., Schmidt, C. G., Achterrath, W., Crooke, S. T: In vivo resistance towards anthracyclines, Etoposide, and cis-diamminedi- chloroplatinum (II). Cancer Res.42, 4719–4725 (1982).PubMedGoogle Scholar
  65. 66.
    Sieber, S. M., Mead, J. A. R., Adamson, R. H: Pharmacology of antitumor agents from higher plants. Cancer Treat. Rep. 60, 1127–1139 (1976).PubMedGoogle Scholar
  66. 67.
    Sieber, S. M., Whang-Peng, M., Botkin, C., Knutsen, T: Teratogenic and cytogenetic effects of some plant-derived antitumor agents (Vincristine, colchicine, maytansine, VP 16-213 and VM 26) in mice. Teratology 18, 31–48 (1978).PubMedCrossRefGoogle Scholar
  67. 68.
    Snodgrass, W., Walker, L., Heideman, R., Odom, L. F., Hays, T., Tubergen, D. G: Kinetics of VP16 epipodophyllotoxin in children with cancer. Proc. Am. Ass. Cancer Res. & Am. Soc. clin. Oncol. 21, 333 (1980).Google Scholar
  68. 69.
    Soloway, M. S., Masters, S. B., Murphy, W. M: Cisplatin analogs and combination chemotherapy in the therapy of murine bladder cancer. In: Cisplatin - Current Status and New Developments (Prestayko, A. W., Crooke, S. T., Carter, S. K., Hrsg.), S. 345. New York-London-Toron- to-Sydney-San Francisco: Academic Press. 1980.Google Scholar
  69. 70.
    Stähelin, H: Activity of a new glucoside lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors. Eur. J. Cancer 9, 215–221 (1973).PubMedCrossRefGoogle Scholar
  70. 71.
    Stähelin, H: Delayed toxicity of epipodophyllotoxin derivatives (VM 26 and VP 16-213), due to a local effect. Eur. J. Cancer 12, 925–931 (1976).PubMedCrossRefGoogle Scholar
  71. 72.
    Stewart, D.M., Richard, M., Hugenholtz, H Dennery, M: VP-16 (VP) and VM 26 (VM) Penetration into Human Brain Tumors (BT). Proc. Am. Ass. Cancer Res. 24, 133, AACR Abstr. 527 (1983).Google Scholar
  72. 73.
    Strife, R.M., Jardine, J: Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography. J. Chrom. 182, 211–220 (1980).CrossRefGoogle Scholar
  73. 74.
    Van de Vyver, F. L., Holthuis, J.M. M., Bekaert, A. B., Verleun, H., Becquart DDe Broe, M. E., Van Oort, W.M: Pharmacokinetic evaluation of increasing dosages of Etoposide (VP 16-213) in a Chronic Hemodialysis Patient. 2nd Eur. Conf. Clin. Oncol., Amsterdam, 2. bis 5. November 1983, S. 14, Abstr. 02–24.Google Scholar
  74. 75.
    Wheeler, K. T., Williams, T. N., Sheppard, S. L., Levin, V. A., Kabra, P. M: Factors influencing the survival of rat brain tumor cells after in vitro treatment with l,3-Bis(2-chloroethyl-)l-nitrosourea. Cancer Res. 35, 1464–1469 (1975).PubMedGoogle Scholar
  75. 76.
    Wolff, S. N., Fer, M. F., McKay, C, Hainsworth, J., Hände, K. R., Greco, F. A: High-dose VP16 and autologous bone marrow transplantation (ABMTX) for advanced malignancies - a phase I study. Proc. Am. Ass. Cancer Res. 23, 134, AACR Abstr. 526 (1982).Google Scholar
  76. 77.
    Wolley, P. V., Schein, P. S: Clinical pharmacology and phase I trial design. In: Methods in Cancer Research XVII: Cancer Drug Development (DeVita, V. D., Busch, H., Hrsg.), Teil B, S. 177. New York-San Francis- co-London: Academic Press. 1979.Google Scholar
  77. 78.
    Wolpert-De Filippes, M. K: Antitumor activity of cis-dichlorodiammine- platinum (II). Cancer Treat. Rep. 63, 1453–1458 (1979).Google Scholar

Copyright information

© Springer-Verlag/Wien 1984

Authors and Affiliations

  • R. Raettig
    • 1
  • N. Niederle
    • 2
  • W. Achterrath
    • 1
  • Gadner
    • 3
  • Lutz
    • 3
  • Raettig
    • 4
  • Schmalzl
    • 5
  • Schwarzmeier
    • 3
  • Willemze
    • 6
  1. 1.Abteilung Klinische Forschung ZytostatikaBristol-Myers GmbHNeu-IsenburgBundesrepublik Deutschland
  2. 2.Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches TumorzentrumUniversitätsklinikum der GHS EssenBundesrepublik Deutschland
  3. 3.WienAustria
  4. 4.Neu-IsenburgDeutschland
  5. 5.InnsbruckAustria
  6. 6.LeidenThe Netherlands

Personalised recommendations